Experimentally induced animal models for cognitive dysfunction and Alzheimer's disease
- PMID: 36479589
- PMCID: PMC9720010
- DOI: 10.1016/j.mex.2022.101933
Experimentally induced animal models for cognitive dysfunction and Alzheimer's disease
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised pathologically by the presence of extracellular amyloid plaques and the intracellular neurofibrillary tangles, along with inflammation, and a compromised antioxidant system. Significant insights into the neurobiology to better understand the pathophysiology of AD and to evaluate the possibility of cutting-edge therapy strategies, can be obtained through the selection of a well-designed experimental animal model. From the transgenic to chemical/drug-induced models, none of them represents the complete picture of Alzheimer pathology and incidence of cognitive dysfunction. Researchers did not explain why one model was preferred over another, did not consider how the pathological phenomena were formed (spontaneously, experimentally, or by genetic manipulation), and did not address the traits of the species that affect the results. There is a lack of concordance between preclinical models and clinical trials that could be due to variety of reasons such as incomplete models, choice of animal species, lack of variability, and the validity of the models. To provide greater translation of preclinical AD studies to clinical trials proper designing of the model is essential. This review provides a brief recap ranging from animal doses to their induction mechanism and common limitations of the chemical-induced AD models. • Animal models may fail to replicate the exact pathology of the disease • Validity of the model is essential for proper translation of pathology from animal models to human disease • Appropriate induction doses need to be administered.
Keywords: Alzheimer's disease; Animal models; Induction dose; Validation.
© 2022 The Author(s).
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Authors declare no conflict of interest.
Similar articles
-
Research on Alzheimer's Disease (AD) Involving the Use of In vivo and In vitro Models and Mechanisms.Cent Nerv Syst Agents Med Chem. 2024 May 27. doi: 10.2174/0118715249293642240522054929. Online ahead of print. Cent Nerv Syst Agents Med Chem. 2024. PMID: 38803173
-
Molecular and functional signatures in a novel Alzheimer's disease mouse model assessed by quantitative proteomics.Mol Neurodegener. 2018 Jan 16;13(1):2. doi: 10.1186/s13024-017-0234-4. Mol Neurodegener. 2018. PMID: 29338754 Free PMC article.
-
Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity.Curr Protoc Pharmacol. 2019 Mar;84(1):e57. doi: 10.1002/cpph.57. Epub 2019 Feb 25. Curr Protoc Pharmacol. 2019. PMID: 30802363 Review.
-
Recent advances in the neurobiology and neuropharmacology of Alzheimer's disease.Biomed Pharmacother. 2018 Feb;98:297-307. doi: 10.1016/j.biopha.2017.12.053. Epub 2017 Dec 27. Biomed Pharmacother. 2018. PMID: 29274586 Review.
-
Amelioration of Alzheimer's disease pathology and cognitive deficits by immunomodulatory agents in animal models of Alzheimer's disease.Neural Regen Res. 2019 Jul;14(7):1158-1176. doi: 10.4103/1673-5374.251192. Neural Regen Res. 2019. PMID: 30804241 Free PMC article.
Cited by
-
Improvement of Cognitive Function by Fermented Panax ginseng C.A. Meyer Berries Extracts in an AF64A-Induced Memory Deficit Model.Nutrients. 2023 Jul 30;15(15):3389. doi: 10.3390/nu15153389. Nutrients. 2023. PMID: 37571326 Free PMC article.
-
Insight into the emerging and common experimental in-vivo models of Alzheimer's disease.Lab Anim Res. 2023 Dec 11;39(1):33. doi: 10.1186/s42826-023-00184-1. Lab Anim Res. 2023. PMID: 38082453 Free PMC article. Review.
-
Diversity of AMPA Receptor Ligands: Chemotypes, Binding Modes, Mechanisms of Action, and Therapeutic Effects.Biomolecules. 2022 Dec 27;13(1):56. doi: 10.3390/biom13010056. Biomolecules. 2022. PMID: 36671441 Free PMC article. Review.
-
MAD-microbial (origin of) Alzheimer's disease hypothesis: from infection and the antimicrobial response to disruption of key copper-based systems.Front Neurosci. 2024 Oct 2;18:1467333. doi: 10.3389/fnins.2024.1467333. eCollection 2024. Front Neurosci. 2024. PMID: 39416952 Free PMC article. Review.
-
New Allosteric Modulators of AMPA Receptors: Synthesis and Study of Their Functional Activity by Radioligand-Receptor Binding Analysis.Int J Mol Sci. 2023 Jun 18;24(12):10293. doi: 10.3390/ijms241210293. Int J Mol Sci. 2023. PMID: 37373440 Free PMC article.
References
-
- McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurol. 1984;34:939–944. doi: 10.1212/wnl.34.7.939. - DOI - PubMed
-
- VeeningGriffioen D.H., Ferreira G.S., VanMeer P.J.K., Boon W.P.C., Wied C.C.Gispen de, Moors E.H.M., Schellekens H. Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer's disease. Eur. J. Pharmacol. 2019;859 doi: 10.1016/j.ejphar.2019.172524. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources